Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a 136-patient 4-week Phase III trial, a 9 g Xyrem dose reduced the number of weekly cataplexy
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury